Laboratories require cost-effective, rapid solutions to track the key SARS-CoV-2 variants currently in circulation globally including Omicron and Delta. While sequencing-based technologies are commonly used, they are highly complex, expensive and have a long turnaround time.
“Agena is proud to continue its support of public health and clinical laboratories in their fight against this pandemic. The MassARRAY System has been used daily to test tens of thousands of samples for COVID-19 under Emergency Use Authorization from the US FDA, and it is suited to rapidly screen millions of COVID-positive samples for key SARS-CoV-2 variants, at a low cost.” – Pete Dansky, President, Agena Bioscience
To meet these challenges, Agena Bioscience has developed the MassARRAY SARS-CoV-2 Variant Panel, a high throughput, low-cost and rapid assay for the detection of 36 unique genetic markers and differentiation of key SARS-CoV-2 variants.
Our panel contains assays for each of the 16 variants, targeting a total of 36 genetic markers!
Get started by completing the online form and we will respond within 24 hours to understand your needs.
The MassARRAY technology is a benchtop system that provides timely and accurate analysis of up to 1000s of samples in a single day. For SARS-CoV-2 and its variant targets, our technology enables accurate detection with comprehensive coverage. Furthermore, the ability to analyze multiple targets in a single assay reduces per-sample cost, scaling your throughput and optimizing supply and resource requirements.
The MassARRAY SARS-CoV-2 Variant Panel is available for Research Use Only (RUO). With exception of the MassARRAY Dx and MassARRAY SARS-CoV-2 Panel, all other products are RUO. Not for use in diagnostic procedures.
We will quickly respond to get you started with the MassARRAY® SARS-CoV-2 Variant Panel.
At Agena Bioscience, we are dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective platform, the MassARRAY® System, provides the capability for targeted genetic assays that satisfy the rigorous demands of genomic testing laboratories.